Physician profile
Shane Tatar
NPI 1770932303
$2,576.34
in general payments reported to CMS, 2019-2025
26 companies · $132 in 2025
The $132 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,320 · 2022: $136 · 2023: $365 · 2024: $623 · 2025: $132.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,120.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $660.90 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $632.19 | 2021-2025 | |
| Glaxosmithkline, LLC. | $292.16 | 2021-2024 | Trelegy Ellipta, Arexvy |
| Intra-Sana Laboratories | $232.49 | 2023-2024 | Reltone 200 Mg, Reltone 400 Mg, Glycate |
| Lilly USA, LLC | $138.01 | 2021-2023 | Mounjaro |
| Astrazeneca Pharmaceuticals LP | $81.02 | 2024-2025 | Airsupra, Farxiga |
| Amarin Pharma, INC. | $57.65 | 2021 | |
| Esperion Therapeutics, INC. | $55.01 | 2021 | |
| Amgen INC. | $53.93 | 2021 | |
| Merck Sharp & Dohme LLC | $50.94 | 2021 | |
| Arbor Pharmaceuticals, INC. | $39.10 | 2021 | |
| Janssen Pharmaceuticals, INC | $33.73 | 2021 | |
| Dexcom, INC. | $23.49 | 2021 | |
| Clarus Therapeutics INC. | $22.33 | 2021 | |
| Abbott Laboratories | $22.04 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $19.99 | 2021 | |
| Heartflow, INC. | $19.46 | 2025 | |
| Corcept Therapeutics | $17.53 | 2021 | |
| Acella Pharmaceuticals, LLC | $17.18 | 2025 | NP Thyroid 60 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.43 | 2021 | |
| Sanofi-Aventis U.S. LLC | $16.19 | 2021 | |
| Alkermes, INC. | $15.61 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $15.22 | 2021 | |
| Redhill Biopharma INC. | $15.22 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.88 | 2021 | |
| Daiichi Sankyo INC. | $13.64 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shane Tatar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.